Table 1.
List of micro-RNA binding sites evaluated in epidemiologic studies
| Single nucleotide polymorphism ID | Gene | Race | Information | Predicted binding site for | Disease | Cases | Controls | Endpoint | Best result | P-value | Assay | Ref |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| rs16917496 | SET8 | AS | T>C (0.32) | miR-502 | NSCLC | 576 | OS (months) OS (RR; 95%CI) |
41.0 vs 58.0 0.44 (0.26–0.74) |
0.031 0.006 |
Gene reporter in vitro assay and IHC on tissues | 27 | |
| rs16917496 | SET8 | AS | T>C (0.32) | miR-502 | SCLC | 44 | OS (RR) | 0.45 (0.22–0.94) | 0.035 | 28 | ||
| rs16917496 | SET8 | AS | T>C (0.32) | miR-502 | BC | 1,100 | AO (years) | 54.6 vs 47.7 | 76 | |||
| rs16917496 | SET8 | AS | T>C (0.32) | miR-502 | HCC | 142 | 142 | Risk (OR; 95%CI) OS (RR) |
NS 0.17 (0.05–0.58) |
NS 0.004 |
IHC in HCC tissues | 107 |
| rs1564483 | BCL2 | AS | G>A (0.29) | miR-181b miR-204 miR-200bc/429 |
NSCLC | 1,017 1,017 |
1,017 | Risk (OR) MST (months) |
0.73 (0.54–0.98) 11.7 vs 15.2 |
0.007 0.036 |
29 | |
| rs2240688 | CD133 | AS | A>C (0.27) | miR-135a/b | LC | 773 503 559 331 |
778 623 |
Risk (OR) Risk (OR) MST (months) MST (months) |
0.80 (0.65–0.98) 0.80 (0.63–1.00) 10 vs 12 14 vs 18 |
0.027 0.05 0.02 0.081 |
Gene reporter in vitro assay + mRNA and IHC on tissue | 35 |
| rs3660 | KRT81 | CAU | C>G (0.41) | miR-20a/b miR-106a/b miR-17 miR-93 miR-519d |
NSCLC SCC |
175 89 |
TTR (months) TTR (months) |
20.3 vs 86.8 23.9 vs 100.2 |
0.003 0.002 |
In silico prediction + IHC on tissues | 17 | |
| rs2239680 | B1RC5 | AS | T>C (0.23) | miR-335 | LC | 600 1,000 |
600 1,000 |
Risk (OR) Risk (OR) |
3.43 (2.04–5.77) 1.63 (1.17–2.26) |
<0.01 <0.01 |
Gene reporter in vitro assay + mRNA and IHC on tissues | 44 |
| rs61764370 | KRAS | HISP CAU |
T>G (0.03) T>G (0.08) |
let-7 | NSCLC | 325 2,205 |
325 1,497 |
Risk (OR) Risk (OR) |
2.3 (1.1–4.6) 1.36 (1.07–1.73) |
0.02 0.01 |
Gene reporter in vitro assay | 45 |
| rs61764370 | KRAS | CAU | T>G (0.08) | let-7 | NSCLC | 218 | OS | NS | 46 | |||
| rs61764370 | KRAS | CAU | T>G (0.08) | let-7 | CRC | 409 (stage I, II) 182 (stage III) 69 (stage IV) |
Risk (RR) OS (HR) NS NS |
0.68 (0.49–0.94) 0.46 (0.18–1.04) |
0.038 | 51 | ||
| rs61764370 | KRAS | CAU | T>G (0.08) | let-7 | CRC | 100 | Responder (%) | 31.9 vs 0.0 | 0.004 | 55 | ||
| rs61764370 | KRAS | CAU | T>G (0.08) | let-7 | BC | 268 (BRCA1 carriers) 89 (BRCA2 carriers) 685 noncarriers |
797 | Risk (OR) Risk (OR) Risk (OR) |
1.47 (1.05–2.06) NS NS |
0.025 | 94 | |
| rs61764370 | KRAS | CAU | T>G (0.08) | let-7 | OC | 100 308 |
101 322 |
Risk (OR) Risk (OR) |
2.38 (1.16–5.09) 2.01 (1.36–2.99) |
0.02 0.0005 |
104 | |
| rs61764370 | KRAS | CAU | T>G (0.08) | let-7 | HNC | 513 | 597 | Risk (OR) OS (HR) |
NS 2.5 (1.3–4.9) |
<0.01 | 126 | |
| rs2735383 | NBS1 | AS | G>C (0.39) | miR-629 | LC | 1,056 503 |
1,056 623 |
Risk (OR) Risk (OR) |
1.47 (1.15–1.86) 1.55 (1.12–2.15) |
0.008 0.026 |
Gene reporter in vitro assay + WB + chromosome aberration challenge assay | 47 |
| rs465646 | REV3L | AS | T>C (0.17) | miR-25 miR-32 |
LC | 500 572 |
517 547 |
Risk Risk |
0.69 (0.53–0.90) 0.72 (0.55–0.94) |
0.007 0.016 |
Cell focus formation assay and gene reporter in vitro assay | 48 |
| rs3134615 | MYCL1 | AS | G>T (0.02) | miR-1827 | SCLC | 666 | 758 | Risk (OR) | 2.08 (1.39–3.21) | 0.0004 | Gene reporter in vitro assay | 50 |
| rs1534862 | NE1L2 | CAU | T>C (0.05) | CRC | 718 229 |
OS (HR) | 1.66 (1.18–2.34) | 0.003 | In silico prediction | 57 | ||
| rs2233921 | SMUG1 | CAU | G>T (0.46) | miR-770-5p miR-665 miR-455-3p |
CRC | 718 229 |
OS (HR) | 0.54 (0.36–0.81) | 0.003 | Gene reporter in vitro assay | 57 | |
| rs10082466 | MBL2 | AA | A>G (0.39) | miR-27a | CRC | 103 | 127 | Risk (OR) | 3.17 (1.57–6.40) | 0.001 | Gene reporter in vitro assay | 1 |
| rs696 | NFkBIA | AS | A>G (0.37) | miR-449 miR-34 |
CRC | 1,001 | 1,005 | Risk (OR) | 1.38 (1.14–1.66) | 0.0008 | Gene reporter in vitro assay | 63 |
| rs70980S | KIAA0182 | CAU | G>A (0.26) | miR-324-3p | CRC | 717 | 739 | Risk (OR) | 1.57 (1.06–2.7) | 0.027 | Gene reporter in vitro assay | 64 |
| rs354476 | NUP210 | CAU | T>C (0.47) | miR-125a miR-125b |
CRC | 717 | 739 | Risk (OR) | 1.36 (1.02–1.82) | 0.0045 | Gene reporter in vitro assay | 64 |
| rs17281995 | CD86 | CAU | G>C (0.12) | miR-337 miR-582 miR-200a miR-184 miR-212 |
CRC | 697 | 624 | Risk (OR) | 2.74 (1.24–6.04) | 0.013 | In silico prediction | 10 |
| rs1051690 | INSR | CAU | G>A (0.14) | miR-618 miR-612 |
CRC | 697 | 624 | Risk (OR) | 1.94 (1.03–3.66) | 0.03 | In silico prediction | 10 |
| rs7356 | RPA2 | CAU | A>G (0.38) | miR-3149 miR-1183 |
CRC | 1,098 | 1,469 | Risk (OR) | 1.33 (1.01–1.75) | 0.04 | In silico prediction | 71 |
| rs4596 | GTF2H1 | CAU | G>C (0.37) | miR-518a-5p miR-527 miR-1205 |
CRC | 1,098 | 1,469 | Risk (OR) | 0.79 (0.64–0.99) | 0.03 | In silico prediction | 71 |
| rs115160714 | TOPBP1 | CAU | C>T (0.005) | miR-3138 miR-4302 miR-1207-5p |
BC | 534 | 556 | Risk (OR) Grading (G3) |
3.54 (1.56–8.39) 6.83 (2.75–16.86) |
0.002 0.0001 |
In silico prediction and mRNA expression + protein on tissue | 78 |
| rs1044129 | RYR3 | AS | A>G (0.44) | miR-367 | BC | 1,532 1,125 |
1,600 | Risk (OR) PFS (HR) |
1.26 (1.03–1.54) 2.20 (1.03–4.70) |
0.028 0.042 |
Gene reporter in vitro assay and IHC on tissues | 84 |
| rs743554 | ITGB4 | CAU | G>A (0.14) | miR-34a | BC | 749 244 |
1,493 | Risk (OR) Grading (G3) HR OS (HR) |
7.65 (1.44–0.7) 2.26 (1.17–4.37) 2.11 (1.21–3.68) |
0.017 0.015 0.0085 |
In silico prediction | 85 |
| rs4245739 | MDM4 | AS | A>C (0.05) | miR-191 | BC | 1,100 1,100 |
1,400 1,400 |
Risk (OR) Risk (OR) |
0.55 (0.40–0.76) 0.41 (0.25–0.67) |
0.00023 0.00031 |
Gene reporter in vitro assay | 87 |
| rs4245739 | MDM4 | AS | A>C (0.05) | miR-191 | OC | 154 113 |
154 | Risk (OR) PFS (months) |
52 vs 82 | NS 0.042 |
Gene reporter in vitro assay + mRNA expression and IHC on tissues | 102 |
| rs4245739 | MDM4 | AS | A>C (0.05) | miR-191 | ESCC | 540 588 |
550 600 |
Risk (OR) Risk (OR) |
0.54 (0.35–0.82) 0.68 (0.44–0.99) |
0.004 0.049 |
mRNA expression on tissue | 137 |
| rs796355l | RAD52 | AS | T>G (0.19) | let-7 b | BC | 878 914 |
900 967 |
Risk (OR) Risk (OR) |
0.85(0.71–1.07) 0.81 (0.68–0.97) |
0.12 0.02 |
Gene reporter in vitro assay | 88 |
| rs799917 | BRCA1 | CAU | C>T (0.34) | miR-638 | BC | 166 (sporadic) 169 (familial) |
186 186 |
Risk (OR) Risk (OR) |
2.81 (1.40–5.61) 1.26(0.59–2.71) |
0.003 NS |
Gene reporter in vitro assay | 90 |
| rs334348 | TGFBR1 | CAU | A>G (0.23) | miR-628-5p | BC | 166 (sporadic) 169 (familial) |
186 186 |
Risk (OR) Risk (OR) |
2.67 (1.19–6.03) 1.26 (0.59–2.71) |
0.002 0.55 |
Gene reporter in vitro assay | 90 |
| rs1042538 | IQGAP1 | AS | A>T (0.43) | miR-124 | BC | 1,541 | 1,598 | Risk (OR) | 0.78 (0.61–0.99) | 0.049 | mRNA and protein expression in frozen tissues | 91 |
| rs2747648 | ESR1 | CAU | T>C (0.042) | miR-453 | BC | 1,223 721 (<50 years old) 438 (high risk fam) |
1,495 713 659 |
Risk (OR) Risk (OR) Risk (OR) |
0.73 (0.54–0.97) 0.60 (0.41–0.89) 0.53 (0.35–0.79) |
0.029 0.010 0.002 |
In silico prediction | 95 |
| rs10889677 | IL23R | AS | A>C (0.33) | Let-7e Let-7f |
BC | 491 491 |
502 | Risk (OR) AO (years) |
1.40 (1.09–1.79) 46.0 vs 50.6 |
0.0084 0.0114 |
In silico prediction | 99 |
| rs17147016 | UGT2A3 | CAU | T>A (0.13) | miR-224 | OC | 417 | 417 | Risk (OR) | 1.47 (1.08–2.01) | 0.015 | In silico prediction | 103 |
| rs7499 | COL18A1 | CAU | G>A (047) | miR-594 | OC | 417 | 417 | Risk (OR) | 1.47 (1.07–2.02) | 0.017 | In silico prediction | 103 |
| rs3917328 | IL1R1 | CAU | C>T (0.04) | miR-335 | OC | 417 | 417 | Risk (OR) | 1.65 (1.03–2.64) | 0.037 | In silico prediction | 103 |
| rs10771184 | KRAS | CAU | T>A (0.45) | miR-544 | OC | 417 417 |
417 | Risk (OR) OS (HR) |
1.26 (1.01–1.57) 0.56 (0.38–0.84) |
0.005 | In silico prediction | 103 |
| rs1425486 | PDGFC | CAU | G>A (0.34) | miR-425 | OC | 417 | OS (HR) | 2.69 (1.67–4.33) | 4.2×10−5 | In silico prediction and gene reporter in vitro assay | 103 | |
| rs1047920 | SNAI1 | CAU | C>T (0.08) | miR-24 | OC | 417 | OS (HR) | 1.96 (1.30–2.97) | 0.0038 | In silico prediction | 103 | |
| rs7869402 | TLR4 | CAU | miR-539 | OC | 417 | OS (HR) | 2.16 (1.31–3.57) | 0.002 | In silico prediction | 103 | ||
| rs17875871 | IFNAR1 | AS | Del (0.12) | miR-1231 | HCC | 420 | 420 | Risk (OR) | 1.84 (1.18–2.84) | 0.006 | In silico prediction | 108 |
| rs3783553 | IL1A | AS | In (0.29) | miR-122 miR-378 |
HCC | 403 1,074 |
434 1,239 |
Risk (OR) Risk (OR) |
0.30 (0.17–0.54) 0.75 (0.57–0.98) |
0.0001 0.0328 |
Gene reporter in vitro assay | 112 |
| rs5622877l | SGSM3 | AS | In ND | miR-151-5p | HCC | 502 | 513 | Risk (OR) | 0.55 (042–0.73) | 1.03×10−5 | In silico prediction and mRNA expression on tissue | 113 |
| rs6147150 | EERB4 | AS | Del ND | let-7c | HCC | 270 | 270 | Risk (OR) | 1.59 (1.22–2.07) | 0.003 | In silico prediction | 114 |
| rs8679 | PARP1 | CAU | T>C (0.21) | miR-145 miR-105 miR-630 miR-302a |
BlC | 752 | 704 | Risk (OR) | 1.29 (1.02–1.62) | 0.05 | In silico prediction | 116 |
| rs7180135 | RAD51 | CAU | A>G (0.44) | miR-197 | BlC | 202 | OS (HR) | 0.52 (0.31–0.87) | 0.01 | In silico prediction | 116 | |
| rs1417608 | HSD3B2 | CAU | A>G (0.07) | miR-423-5p miR-1914 miR-3658 |
BlC | 563 497 |
863 957 |
Risk (OR) Risk (OR) |
1.94 (1.36–2.75) 3.66 (1.06–12.63) |
0.001 0.04 |
In silico prediction | 117 |
| rs9299 | HOXB5 | CAU | A>G (0.37) | miR-7 | BlC | 391 | 391 | Risk (OR) Grading (T2–T4) |
2.05 (1.06–3.94) 2.25 (1.33–3.79) |
0.031 0.003 |
Gene reporter in vitro assay | 121 |
| rs88422S | EGFR | AS | A>G (0.39) | miR-214 | BlC | 908 | 1,239 | Risk (OR) | 1.40 (1.09–1.80) | 0.008 | Gene reporter in vitro assay | 122 |
| rs3747238 G allele |
SMC1B | CAU | T>C (0.46) | miR-609 miR-124a |
HNC | 150 with recurrence 300 w/t recurrence |
ROR (HR) TTR (months) |
1.74 (1.19–2.54) >93 vs 75.8 |
0.004 0.019 |
In silico prediction | 125 | |
| rs8126 | TNFA1P2 | CAU | T>C (0.37) | miR-184 | HNC | 1,077 | 1,073 | Risk (OR) | 1.48 (1.06–2.05) | 0.02 | Gene reporter in vitro assay + mRNA expression on tissue | 127 |
| rs8126 | TNFA1P2 | CAU | T>C (0.37) | miR-184 | GC | 301 | 313 | Risk (OR) | 2.00 (1.09–3.64) | 0.024 | 130 | |
| rs712 | KRAS | AS | T>G (0.18) | let-7 | GC | 118 | 674 | Risk (OR) | 3.05 (1.53–6.08) | 0.00153 | 131 | |
| rs12537 | MTMR3 | AS | C>T(0.23) | miR-181a | GC | 500 | 502 | Risk (OR) OS (HR) |
1.72 (1.36–2.16) 1.38 (1.03–1.83) |
3.99×10−5 0.029 |
Gene reporter in vitro assay | 132 |
| rs6573 | RAP1A | AS | C>A (0.11) | miR196a | ESCC | 536 | 608 | Risk (OR) | 0.43 (0.21–0.91) | 0.02 | Gene reporter in vitro assay | 135 |
| rs1131445 | IL16 | AA | T>C (0.25) | miR-135a/b | PC | 256 | OS (HR) | 3.0 (1.23–7.12) | 0.014 | 137 | ||
| rs11902171 | ITGAv | AS | G>C (0.08) | PC | 347 | 367 | Risk (OR) | 0.57 (0.35–0.93) | 0.024 | 141 | ||
| rs1434536 | BMPR1B | AS | C>T (0.34) | miR-125b | PC | 247 | 278 | Risk (OR) | 1.90 (1.15–3.15) | 0.015 | Gene reporter in vitro assay | 143 |
Notes: The results are reported for the less common (underlined) allele, using the most common allele as reference. The table resumes the best associations reported in the cited study.
Abbreviations: ID, identification number; Ref, reference; AS, Asian; T, timeline; miR, microRNA; NSCLC, non-small-cell lung cancer; OS, overall survival; RR, relative risk; IHC, immunohistochemistry; SCLC, small cell lung cancer; BC, breast cancer; AO, age of onset; HCC, hepatocellular carcinoma; OR: odds ratio; NS, statistically nonsignificant; LC, lung cancer; MST, median survival time; mRNA, messenger RNA; CAU, Caucasian; SCC, squamous cell carcinoma; TTR, time to recurrence; HIS, Hispanic; HR, hazard ratio; CRC, colorectal cancer; OC, ovarian cancer; HNC, head and neck cancer; WB, western blot; AA, African American; PFS, progression-free survival; ND, not detected; BlC, bladder cancer; ROR, risk of recurrence; GC, gastric cancer; ESCC, esophageal cancer; PC, prostate cancer ; vs, versus; fam, familiar; In, insertion; Del, deletion; w/t, without.